---
title: GA News
description: Bausch + Lomb acquires Whitecap Biosciences to enhance glaucoma and GA therapies, while Aviceda secures $207.5M for AVD-104 trials.
---

[Vision Executives Blog](https://visionexecutives.com/blog)

# [GA News](https://visionexecutives.com/blog/ga-news)

 Written by [Vision Executives](https://visionexecutives.com/blog/author/vision-executives) | Jan 29, 2025 2:43:07 PM

𝐆𝐀 𝐍𝐞𝐰𝐬

👀 𝐁𝐚𝐮𝐬𝐜𝐡 + 𝐋𝐨𝐦𝐛 𝐀𝐜𝐪𝐮𝐢𝐫𝐞𝐬 𝐖𝐡𝐢𝐭𝐞𝐜𝐚𝐩 𝐁𝐢𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬  
[Bausch + Lomb](https://www.linkedin.com/company/bausch-%26-lomb/) has announced the acquisition of Whitecap Biosciences, LLC, which is currently developing 2 therapies for potential use in glaucoma and geographic atrophy (GA). This acquisition aims to enhance Bausch + Lomb’s clinical-stage pipeline with innovative treatments targeting two of the leading causes of blindness in ophthalmology.

<https://www.linkedin.com/in/ACoAAAE1LYgBm_Yko6U7APaLNVkiGi4TN4WUl9U>[Yehia Hashad MD](https://www.linkedin.com/in/yehia-hashad-md-a349516/), MD, Chief Medical Officer and Executive Vice President of research & development at Bausch + Lomb, stated, “Glaucoma and geographic atrophy are two areas where we believe that dramatic improvement is possible. Whitecap Biosciences’ investigational medicines show real promise when it comes to slowing vision loss and perhaps even improving vision for patients with glaucoma, which would be a long-overdue breakthrough.”

👀 𝐀𝐯𝐢𝐜𝐞𝐝𝐚 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 $207.5𝐌 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐀𝐕𝐃-104 𝐟𝐨𝐫 𝐆𝐞𝐨𝐠𝐫𝐚𝐩𝐡𝐢𝐜 𝐀𝐭𝐫𝐨𝐩𝐡𝐲 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭  
[Aviceda Therapeutics](https://www.linkedin.com/company/aviceda-therapeutics/) has successfully secured $207.5 million in Series C financing to support its ongoing Phase 2b and Phase 3 clinical trials of AVD-104 for geographic atrophy (GA).

The ongoing phase 2b/3 trial is evaluating the safety and efficacy of high and low dose AVD-104 compared to avacincaptad pegol (IZERVAY) in patients with GA. Enrolment for this study was completed in September 2024, and 12-month primary endpoint data is anticipated in the second half of 2025. With the backing of this investment, Aviceda is well-positioned to advance AVD-104 through pivotal clinical trials, bringing it closer to potential regulatory approval.

[View full post](https://visionexecutives.com/blog/ga-news)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Vision Executives"
  },
  "dateModified" : "2025-01-29T14:43:15.191Z",
  "datePublished" : "2025-01-29T14:43:07Z",
  "headline" : "GA News",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1080,
    "url" : "https://139544819.fs1.hubspotusercontent-eu1.net/hubfs/139544819/GA%20News.png",
    "width" : 1080
  },
  "mainEntityOfPage" : "https://visionexecutives.com/blog/ga-news",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Vision Executives Blog"
  }
}
```